{
  "source": "PA-Notification-Vanflyta.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1417-2\nProgram Prior Authorization/Notification\nMedication Vanflyta® (quizartinib)\nP&T Approval Date 9/2023, 9/2024\nEffective Date 11/17/2024\n1. Background:\nVanflyta (quizartinib) is a kinase inhibitor indicated in combination with standard cytarabine\nand anthracycline induction and cytarabine consolidation, and as maintenance monotherapy\nfollowing consolidation chemotherapy, for the treatment of adult patients with newly diagnosed\nacute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as\ndetected by an FDA-approved test. NCCN also recommends Vanflyta for the treatment of\nrelapsed/refractory disease as a component of repeating the initial successful induction regimen\nor as a single agent.\nLimitations of Use:\nVanflyta is not indicated as maintenance monotherapy following allogeneic hematopoietic stem\ncell transplantation (HSCT); improvement in overall survival with Vanflyta in this setting has\nnot been demonstrated.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age\nof 19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Vanflyta will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Acute Myeloid Leukemia\n1. Initial Authorization\na. Vanflyta will be approved based on all of the following criteria:\n(1) Diagnosis of acute myeloid leukemia (AML)\n© 2024 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) Disease is FLT3 internal tandem duplication (ITD) posi",
    "approved based on all of the following criteria:\n(1) Diagnosis of acute myeloid leukemia (AML)\n© 2024 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) Disease is FLT3 internal tandem duplication (ITD) positive\n-AND-\n(3) One of the following:\ni. Vanflyta will be used in combination with standard cytarabine and\nanthracycline induction and cytarabine consolidation, and as maintenance\nmonotherapy following consolidation chemotherapy\n-OR-\nii. Vanflyta will be used for patients with relapsed/refractory disease as a\ncomponent of repeating the initial successful induction regimen or as a\nsingle agent.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Vanflyta will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Vanflyta\ntherapy\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B.\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limit may be in place.\n© 2024 UnitedHealthcare Services, Inc.\n2\n4. References:\n1. Vanflyta [package insert]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; July 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org . Accessed August 8, 2024.\nProgram Prior Authorization/Notification - Vanflyta (quiz",
    "i Sankyo, Inc.; July 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org . Accessed August 8, 2024.\nProgram Prior Authorization/Notification - Vanflyta (quizartinib)\nChange Control\n9/2023 New program\n9/2024 Annual review. Added coverage on relapsed/refractory disease per NCCN\nrecommendations. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}